Loading…
Employees: 54
Size TenNor Therapeutics Suzhou (6872.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $470M, the 763rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$69.30 on 18 Nov 2026.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | HK$0 | HK$0 | HK$0 |
| Revenue growth | — | — | — | — |
| Gross profit | n/a | -HK$1.72M | -HK$2.92M | -HK$3.19M |
| EBITDA | n/a | -HK$129M | -HK$87.0M | -HK$138M |
| Net income | n/a | -HK$166M | -HK$158M | -HK$212M |
| Free cash flow | n/a | -HK$96.4M | -HK$55.0M | -HK$111M |
| Capital expenditure | n/a | HK$491,289 | HK$220,097 | HK$566,864 |
| Total debt | n/a | HK$31.9M | HK$1.05B | HK$910M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6872.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -32.8% | -9.5% | 2nd lowest of 21 |
| Distance from 52-week high | -75.8% | -41.1% | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| Kamada KMDA | United States | $465M | +3% | +5% | 15% | 2.0× | 5.0% | +6.5% |
| DiaMedica Therapeutics DMAC | United States | $463M | +50% | n/a | n/a | n/a | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $462M | n/a | n/a | -4,673% | 509.6× | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | 22.7× | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | 13.3× | n/a | n/a |
| Shattuck Labs STTK | United States | $455M | -28% | -100% | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $454M | -2% | -6% | -1% | 11.8× | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | 8,281.1× | n/a | n/a |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | 84.4× | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 5.2× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | 6.2× | 29.4% | +7.0% |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | 9.9× | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 7.5× | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | 3.3× | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 2.2× | 7.7% | +7.3% |